BICO Group AB Class B stock analysis
BICO Group AB Class B (49Z) Stock Price & Analysis
49Z Stock Chart & Stats
- Day’s Range
- EUR 1.42 - EUR 1.48
- 52-Week Range
- EUR 1.19 - EUR 2.30
- Previous Close
- EUR 1.43
- Volume
- N/A
- Average Volume (3M)
- 225
- Market Cap
- EUR 98.49M
- Enterprise Value
- EUR 1.68B
- Total Cash (Recent Filing)
- EUR 554.90M
- Total Debt (Recent Filing)
- EUR 697.30M
- Price to Earnings (P/E)
- ―
- Beta
- 0.76
- Next Earnings
- Feb 17, 2027 (Est.)
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Precision-biology Strategy
The sharper focus on precision biology and 3D cell models could improve capital allocation by concentrating resources where BICO sees stronger competitive advantages. Over time, this may support more differentiated products, better returns on R&D, and a clearer path to profitable organic growth.
Net Cash Balance
A net cash position provides financial flexibility while the company restructures and invests in product launches. It also reduces immediate dependence on external funding and offers greater capacity to absorb operating volatility, pursue focused development, and manage the Biosero reset.
Recurring Revenue Potential
Increasing consumables, services, and software should make revenue more repeatable and less dependent on irregular customized projects. A larger recurring component can improve customer retention, support steadier cash generation, and strengthen the economics of BICO's installed instrument base over several quarters.
Bears Say
Persistent Unprofitability
Improved gross margin has not yet translated into sustainable earnings because operating costs and other items continue to outweigh gross profit. Persistent losses limit internal funding capacity, weaken returns on equity, and leave profitability dependent on further execution and cost improvements.
Weak Cash Conversion
Near-breakeven operating cash flow and negative free cash flow show that accounting progress is not yet converting reliably into liquidity. If this persists, BICO may have less flexibility to fund growth, absorb project volatility, or invest in product development without using its cash reserves.
Biosero Underperformance
Biosero's weaker sales, order intake, and project profitability indicate that the platform has not delivered the expected growth or economics. The impairment and strategic reassessment raise execution uncertainty and may divert management attention while the long-term role of the business is determined.
BICO Group AB Class B News
49Z FAQ
What was BICO Group AB Class B’s price range in the past 12 months?
What is BICO Group AB Class B’s market cap?
When is BICO Group AB Class B’s upcoming earnings report date?
How were BICO Group AB Class B’s earnings last quarter?
Is BICO Group AB Class B overvalued?
Does BICO Group AB Class B pay dividends?
What is BICO Group AB Class B’s EPS estimate?
How many shares outstanding does BICO Group AB Class B have?
What happened to BICO Group AB Class B’s price movement after its last earnings report?
Which hedge fund is a major shareholder of BICO Group AB Class B?
What is the TipRanks Smart Score and how is it calculated?
Company Description
BICO Group AB Class B
BICO Group AB (publ) is a global bio-convergence enterprise, extending its operations across North America, Europe, Asia, and other international markets. Its business is segmented into two primary divisions: Laboratory Solutions and Bioautomation. The Laboratory Solutions division equips researchers with advanced tools like 3D bioprinters, hybrid microscopes, and instruments for single-cell dispensing and liquid handling. It also supplies essential consumables such as bioinks, reagents, microscope lenses, and specialized software, alongside 3D reconstructed human tissues crucial for regulatory testing. Furthermore, this segment provides specialized services in 3D cell culture, tissue imaging, multiplex imaging, and digital pathology, primarily benefiting pharmaceutical and biotechnology firms. Conversely, the Bioautomation segment caters to industrial clients with precision dispensing and biosensor technologies, while also delivering diagnostic automation and sophisticated robotics solutions to the medical and diagnostics sectors. Beyond these segments, BICO Group's comprehensive portfolio includes solutions for tissue engineering, multi-omics, cell line development, and diagnostics, contributing to a robust industrial ecosystem. Its principal clientele spans the medical, pharmaceutical, and cosmetic industries. Originally established in 2016 as Cellink AB (publ), the company adopted its current name, BICO Group AB (publ), in August 2021. Its headquarters are located in Gothenburg, Sweden.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Anders Fogelberg
- Employees
- 554
- Website
- www.bico.com
- Address
- Grafiska vägen 2B, Gothenburg, VG, 412 63, SE
BICO Group AB Class B (49Z) Earnings & Revenues
49Z Company Deck
49Z Earnings Call
Earnings Call SentimentNeutral
The call presented a strong Q3 with 19% organic sales growth, 14% growth in own benchtop instruments, a 27% adjusted EBITDA margin, restructuring progress, and a clear new precision-biology strategy. However, reported profitability benefited materially from a one-time SCIENION agreement, operating cash flow was negative, working capital was elevated, academic demand remained weak, and Biosero required a substantial SEK 296 million impairment and strategic reassessment. Overall, the positive operating momentum and strategic clarity were offset by significant execution, cash conversion, and Biosero-related challenges.
View all DE:49Z earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 1 | 15 |
| Technical Analysis | 6 | 1 | 3 |
| Moving Averages | 0 | 0 | 12 |











